We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
-4.81%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
-$87.1M
Cap. Flow
-$47.5M
Cap. Flow %
-16.99%
Top 10 Hldgs %
59.73%
Holding
57
New
12
Increased
11
Reduced
3
Closed
20

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.9M
2
MRUS
Merus
MRUS
+$18.4M
3
NUVL
Nuvalent
NUVL
+$17.6M
4
SLNO
Soleno Therapeutics
SLNO
+$11.4M
5
RVMD icon
Revolution Medicines
RVMD
+$9.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$82M
2
NVO
Novo Nordisk
NVO
+$58.6M
3
VKTX icon
Viking Therapeutics
VKTX
+$25.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.79M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.89M

Sector Composition

Rank Sector Weight
1 Healthcare 88.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$7.07B
$1.64M 0.59%
+54,515
New +$1.56M
EYPT icon
27
EyePoint Inc
EYPT
$1.04B
$1.61M 0.58%
216,700
+60,400
+39% +$562K
XENE icon
28
Xenon Pharmaceuticals
XENE
$6.02B
$1.57M 0.56%
40,000
– –
MREO
29
Mereo BioPharma
MREO
$50.4M
$1.47M 0.53%
421,359
– –
NAMS icon
30
NewAmsterdam Pharma
NAMS
$3.21B
$1.4M 0.5%
54,285
– –
CNTA
31
DELISTED
Centessa Pharmaceuticals
CNTA
$1.35M 0.48%
80,380
– –
EWTX icon
32
PUT
Edgewise Therapeutics
EWTX
$4.13B
$1.33M 0.48%
+50,000
New +$1.59M
CRL icon
33
Charles River Laboratories
CRL
$11.1B
$1.16M 0.42%
6,305
– –
TARS icon
34
Tarsus Pharmaceuticals
TARS
$2.68B
$1.15M 0.41%
+20,811
New +$945K
ASND icon
35
Ascendis Pharma A/S
ASND
$16B
$1.02M 0.37%
7,440
– –
ANNX icon
36
Annexon
ANNX
$860M
$884K 0.32%
172,226
– –
TECX
37
Tectonic Therapeutic
TECX
$527M
$769K 0.27%
+16,650
New +$704K
ALEC icon
38
Alector
ALEC
$168M
– –
-193,317
Closed -$901K
AXSM icon
39
Axsome Therapeutics
AXSM
$10.9B
– –
-87,848
Closed -$7.89M
CLDX icon
40
Celldex Therapeutics
CLDX
$2.96B
– –
-75,300
Closed -$2.56M
CRBP icon
41
Corbus Pharmaceuticals
CRBP
$165M
– –
-47,400
Closed -$978K
DYN icon
42
Dyne Therapeutics
DYN
$4.71B
– –
-119,488
Closed -$4.29M
IDYA icon
43
IDEAYA Biosciences
IDYA
$3.41B
– –
-62,992
Closed -$2M
IONS icon
44
Ionis Pharmaceuticals
IONS
$9.06B
– –
-30,479
Closed -$1.22M
IRON icon
45
Disc Medicine
IRON
$2.93B
– –
-13,440
Closed -$660K
KROS icon
46
Keros Therapeutics
KROS
$200M
– –
-20,000
Closed -$1.16M
KURA icon
47
Kura Oncology
KURA
$816M
– –
-57,178
Closed -$1.12M
LLY icon
48
Eli Lilly
LLY
$1,000B
– –
-92,593
Closed -$82M
LLY icon
49
PUT
Eli Lilly
LLY
$1,000B
– –
-15,000
Closed -$13.3M
LRMR icon
50
Larimar Therapeutics
LRMR
$413M
– –
-90,490
Closed -$593K
1
2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Artia Global Partners held 57 positions worth $280M, down 24% from $367M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artia Global Partners withdrew a net $47.5M in Q4 2024, closing 20 positions and reducing 3 holdings. Its most notable exit was Eli Lilly, an estimated $82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 96% a quarter earlier.

Against the trend, Artia Global Partners opened a new position in Arcellx worth $17.6M.

  • Artia Global Partners's largest Q4 2024 buy was Arcellx: 229,785 shares worth $17.6M.
  • Artia Global Partners added most to Merus in Q4 2024, an estimated $18.4M increase.
  • Artia Global Partners's biggest Q4 2024 reduction was Novo Nordisk, cutting an estimated $58.6M.
  • Artia Global Partners fully exited Eli Lilly in Q4 2024, selling an estimated $82M.
  • Artia Global Partners's ten largest holdings make up 60% of its $280M portfolio in Q4 2024.
  • Artia Global Partners opened 12 new positions and closed 20 in Q4 2024.
  • Artia Global Partners's portfolio value fell 24% quarter-over-quarter to $280M.

Based on Artia Global Partners's 13F filing for Q4 2024, filed 14 Feb 2025.